Last reviewed · How we verify
Granisetron and dexamethasone
Granisetron blocks 5-HT3 receptors to prevent nausea and vomiting, while dexamethasone suppresses inflammatory cytokines and enhances antiemetic effects.
Granisetron blocks 5-HT3 receptors to prevent nausea and vomiting, while dexamethasone suppresses inflammatory cytokines and enhances antiemetic effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients receiving emetogenic chemotherapy.
At a glance
| Generic name | Granisetron and dexamethasone |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | 5-HT3 receptor antagonist + corticosteroid combination |
| Target | 5-HT3 receptor (granisetron); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Granisetron is a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Dexamethasone is a corticosteroid that reduces inflammation and potentiates antiemetic activity through multiple pathways. Together, this combination targets chemotherapy-induced nausea and vomiting (CINV) through complementary mechanisms.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients receiving emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Diarrhea
- Insomnia
- Hyperglycemia
Key clinical trials
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (PHASE3)
- Granisetron Combined With Dexamethasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecystectomy (PHASE4)
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (PHASE4)
- BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron (PHASE4)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
- The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Granisetron and dexamethasone CI brief — competitive landscape report
- Granisetron and dexamethasone updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI